Autopsy report · NCT04200066

A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma

“One of the drugs for the study is not commercially available.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

University of Rochester

Sponsor type

University, hospital or other

Conditions

Glioblastoma; Brain Tumor

Interventions

Temozolomide, Tamoxifen, Maprotiline

Participants

0

Trials that died the same way

• P1101 in Treating Patients With Myelofibrosis
  “Study drug became commercially available” (78% match in meaning)
• Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer
  “No study drug available. Same concept with new study drug will be explored in M19TGA study” (75% match in meaning)
• An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC
  “The study drug, Famitinib, was not marketed and the drug was not available.” (75% match in meaning)
• Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
  “Study drug is now commercially available in tablet format” (75% match in meaning)
• Iontophoresis in Psoriasis
  “FDA did not provide approval of the use of the drug for the study” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.